Here, we overview the two categories of neoantigens, i.e., private and shared, and their use in immuno-oncotherapy in selected pre-clinical and clinical studies. The vast majority of commonly occurring tumor-specific mutations are cancer causing and are permanently expressed by all malignant ...
1. Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023 Jan 6;8(1):9. doi: 10.1038/s41392-022-01270-x. 2. Zhang Z, et al. Neoantigen: a new ...
Realising the Promise: Neoantigens in cancer immunotherapySchumacher, Ton NSchreiber, Robert D
These observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens. 展开 ...
Recently, the advancement of technologies has contributed to scientific discoveries around cancer development, progression, immune evasion and crosstalk with the tumour microenvironment. New approaches of cancer therapies such as immunotherapy, which leverages the patient’s immune system in fighting cancer ...
Targeting public neoantigens for cancer immunotherapy Article17 May 2021 Introduction Accumulating genetic alterations in cancers result in the production of tumor-specific antigens (TSAs) or neoantigens, which can be presented by major histocompatibility (MHC) molecules of tumor cells.1,2,3,4,5,6...
et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015). CAS PubMed PubMed Central Google Scholar Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–...
Schreiber Neoantigens in cancer immunotherapy Science, 348 (6230) (2015), pp. 69-74 CrossrefView in ScopusGoogle Scholar 21. M.A. Hall Correlation-based feature selection of discrete and numeric class machine learning (Working paper 00/08) Hamilton New Zealand University of Waikato Department ...
Neoantigen Peptides in Cancer Immunotherapy: Neoantigen peptides play a pivotal role in advancing cancer treatment through personalized vaccines. These vaccines are tailored to activate the immune system against cancer cells expressing specific neoantigens, aiming to control tumor growth and potentially indu...
In 2010, APCs loaded with a tumor antigen was approved Immune targets and neoantigens for cancer immunotherapy and precision medicine 12 by US Food and Drug Administration (FDA) for the treatment of metastatic prostate cancer. However, be- cause of the expensive cost and limited extension of pa...